Brighter announces commercial launch and availability of Actiste® in Qatar.
Brighter AB (Publ) (The Company) today announced the launch and commercial availability of its Actiste® service, aiming to improve the quality of life for people living with diabetes in Qatar.
The company's distributor in Qatar – Al Danah Medical Company – has placed an initial order for a small number of Actiste® devices, which will shortly be shipped to the country. The value of the order is not material but besides being the first Actiste® devices that will be offered to diabetes patients in Qatar, the shipment is also a part of validating the processes that Brighter has in place – all the way from the factory to the end user.
“All of us at Brighter are truly proud to be able to offer this solution to patients living with diabetes. Besides from a tremendous effort by the Brighter team I am thankful to our distributor whose participation and support in the process has led to this milestone” commented Erik Lissner, acting CEO of Brighter AB.
The company believes that the Actiste® solutions, registered to be used by adults with diabetes could also, in the future, create new opportunities and value for a broad group of stakeholders: relatives, healthcare providers, authorities and governments, insurance companies and employers, the pharmaceutical industry, clinical-research organizations, and academic organizations. However, to secure sales and future revenue, collaboration with key healthcare providers is essential.
“We consider the availability of the Actiste® service an important advancement towards meeting the current demands for increased efficiency and new innovative digital solutions. Both for people living with diabetes as well as for the health care sector as a whole, '' commented Erik Lissner. “Now we need to continue our sales focus and talk to key healthcare providers, who can validate, prescribe and promote the Actiste® service to patients.”
The company is also working closely with its distributor who, once validation of the product is done, will be able to take part in public procurement bids.
For further information, please contact:
Investor Relations
ir@brighter.se
Certified Adviser
Brighter’s Certified Adviser är Mangold Fondkommission AB,
+46 8 5277 5020, ca@mangold.se, www.mangold.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/.